Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50a09e48366aa06b1a5cddf4a655fc7b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-10001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 |
filingDate |
2013-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7c307a55f457595a42ffbcc5e718734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b73fd8b42bdbcbe1061a7ac7abdc43c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1781a8369676384aa3949d208d5a9733 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24c414ffc817da34da0f88fa2b6a81c3 |
publicationDate |
2015-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-2838998-A1 |
titleOfInvention |
Egfr and ros1 in cancer |
abstract |
The present disclosure provides methods of that include detecting in a biological sample from a patient having or suspected of having cancer the presence of a polypeptide having ROSl kinase activity or a polynucleotide encoding the same and detecting in the biological sample the presence of a mutant EGFR polypeptide or a polynucleotide encoding the same. In some aspects, the disclosure provides methods of treating a patient for cancer that include determining that a biological sample from a tumor in the patient includes a polypeptide having ROSl kinase activity or a polynucleotide encoding the same and a mutant EGFR polypeptide or a polynucleotide encoding the same and administering to the patient a therapeutically effective amount of a ROSl inhibitor and an EGFR inhibitor, thereby treating the patient for cancer. |
priorityDate |
2012-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |